Dianthus Therapeutics ( (DNTH) ) has issued an update.
On March 4, 2025, Dianthus Therapeutics announced the resignation of Tomas Kiselak from its Board of Directors, which was not due to any disagreements with the company. The same day, Sujay Kango was appointed as a Class II director and a member of the Compensation Committee, receiving stock options and cash compensation in line with the company’s policies.
More about Dianthus Therapeutics
YTD Price Performance: -14.40%
Average Trading Volume: 231,326
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $587.8M
For detailed information about DNTH stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com